Ep. 172: Nina Deka: Innovations In Healthcare Technology
Investing With IBD
00:00
The Growth Opportunity in Next Gen Sequencing
There's been over $15 billion of M&A right now in the genomics companies acquiring this liquid biopsy space. Liquid biopsy is basically if you were to draw blood, you could analyze that blood and look for pieces of DNA. Minimum residual disease is another huge growth area. And yet there's still so much innovation and upside happening there that it's really a compelling time to take a long position in these companies.
Transcript
Play full episode
